2[2]Ayata G, Gordon FD, Lewis WD, et al. Cryptogenic cirrho_sis: clinicopathologic findings at and after liver transplanta_tion. Hum Pathol, 2002, 33:1098
5[5]McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol, 2002, 34:255
6[6]Falck- Ytter Y, Younossi Z, Marchesini G, et al. Clinical features and natural history of nonalcoholic steatosis syndro_mes. Semin Liver Dis, 2001, 21:17
7[7]Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapy. Semin Liver Dis, 2001, 21: 81
8[8]Marchesini G, Brizi M, Bianchi G, et al. Metformin in non_alcoholic steatohepatitis. Lancet, 2001, 358:893
9[9]Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol, 1999, 31:384
10[10]Harlander JC, Kwo PY, Cummings OW. Atorvastin for the treatment of NASH. Gastroenterology, 2001, 120:A2767